

Clinical Trial Protocol

Iranian Registry of Clinical Trials

20 Jul 2026

Randomized, single-dose, crossover comparative bioequivalence study of Gliclazide 30 mg MR tablet of ACTOVERCO and Servier Inc. in 24 healthy male under fasting conditions

Protocol summary

Study aim

This study was performed to compare the pharmacokinetics and invivo parameters of Gliclazide 30 mg formulation as a test product with Diamicron® tablet formulation as a reference product and to evaluate the biocompatibility of these two formulations.

Design

Randomized, single-dose, crossover comparative bioequivalence study of Gliclazide 30 mg F.C. tablets of Actover. and Sanofi. in 24 healthy male under fasting.

Settings and conduct

In each period, volunteers will receive a single dose of the treatment in the Noor Research and Development Institute (Tarasht, Tehran). 2 dosing periods will be separated by a 7-day washout period.

Participants/Inclusion and exclusion criteria

Inclusion Criteria: Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18.5 and 30 (inclusive), calculated as kg/m². Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations. Subjects with normal vital signs. Exclusion Criteria: Acute infection within one week preceding first study drug administration. A known hypersensitivity to gliclazide or its analogues. Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period.

Intervention groups

Intervention group: Intervention group (test):Gliclazide 30 mg tablet, produced by Actover. is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product. Intervention group (Reference): Diamicron® tablet, produced by Servier is the reference product. In each period, 12 of 24 subjects will be given single oral dose of this product.

Main outcome variables

Peak Plasma Concentration

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20180620040164N53**

Registration date: **2023-11-23, 1402/09/02**

Registration timing: **prospective**

Last update: **2023-11-23, 1402/09/02**

Update count: **0**

Registration date

2023-11-23, 1402/09/02

Registrant information

Name

Behzad Montaha Sangari

Name of organization / entity

Noor research and educational institute (Tavan)

Country

Iran (Islamic Republic of)

Phone

+98 21 6600 7026

Email address

info@tavaninstitute.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-01-21, 1402/11/01

Expected recruitment end date

2024-02-03, 1402/11/14

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Randomized, single-dose, crossover comparative bioequivalence study of Gliclazide 30 mg MR tablet of ACTOVERCO and Servier Inc. in 24 healthy male under fasting conditions

Public title

bioequivalence study of Gliclazide 30 mg MR tablet in 24 healthy male under fasting conditions

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18.5 and 30 (inclusive), calculated as kg/m². Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations. Subjects with normal vital signs. Subjects who agree with patient consent form.

Exclusion criteria:

Subject has a history of significant asthma, peptic or gastric ulcer, sinusitis, pharyngitis, renal disorder (impaired renal function), hepatic disorder (impaired hepatic function), cardiovascular disorder, neurological disease such as epilepsy, hematological disorders or diabetes, psychiatric, dermatologic or immunological disorders. Acute infection within one week preceding first study drug administration. A known hypersensitivity to gliclazide or its analogues. Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period. Subjects who has used any drug including prescription or Over-The-Counter (OTC) drugs within 14 days prior to the start of the study and might need drug intake during study period. History of alcohol or drug abuse within 2 years before the start of the study. Heavy drinker of caffeine, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity. A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study.

Age

From **20 years** old to **45 years** old

Gender

Male

Phase

Bioequivalence

Groups that have been masked

No information

Sample size

Target sample size: **24**

Randomization (investigator's opinion)

Randomized

Randomization description

The randomization schedule will be generated with <https://www.sealedenvelope.com/simple-randomiser/v1/li> sts. A 2*2 block randomization list is created. We have 12 blocks and within each two volunteer numbers (allocated after screening) for all 24 volunteers. According to this list, a treatment sequence of Test/Reference or Reference/Test will be given to each volunteer.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Crossover

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Shahid Beheshti University of Medical Sciences

Street address

Niayesh Highway, Valiasr Ave, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1996835113

Approval date

2021-08-31, 1400/06/09

Ethics committee reference number

IR.SBMU.PHARMACY.REC.1400.128

Health conditions studied**1****Description of health condition studied**

diabetes mellitus

ICD-10 code

E10

ICD-10 code description

Type 1 diabetes mellitus

Primary outcomes**1****Description**

Peak Plasma Concentration (C_{max})

Timepoint

During 2 months after intervention

Method of measurement

using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA)

Secondary outcomes

1

Description

AUC (Area Under the Concentration-Time Curve)

Timepoint

During 2 months after intervention

Method of measurement

using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA)

Intervention groups

1

Description

Intervention group (test): Gliclazide 30 mg tablet, produced by Actover is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product.

Category

Treatment - Drugs

2

Description

Intervention group (reference): Gliclazide 30 mg tablet, produced by Servier is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product.:

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Noor Research & Development Institute (Tavan)

Full name of responsible person

Ali Aghaei

Street address

Sharif Innovation Station, North Habibollah Street, Hosseini Square, Teymouri Street, Tarasht.

City

Tehran

Province

Tehran

Postal code

1459926609

Phone

+98 21 6600 4027

Email

info@tavaninstitute.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

ACtover Pharmaceutical Co.

Full name of responsible person

Dr. Ramin Daneshmir

Street address

No. 58, 8th St., Gisha

City

Tehran

Province

Tehran

Postal code

1446863914

Phone

+98 21 4162 7000

Email

info@actoverco.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

ACtover Pharmaceutical Co.

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Noor Research & Development Institute

Full name of responsible person

Ali Aghaei

Position

Master

Latest degree

Master

Other areas of specialty/work

Pharmacy

Street address

Sharif innovation station, North Habibollah, Hosseini Squ., Teymouri St., Tarasht

City

Tehran

Province

Tehran

Postal code

1459926609

Phone
+98 21 6600 4027
Email
info@tavaninstitute.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tavan Institute
Full name of responsible person
Seyed Mohsen Foroutan
Position
Principal investigator
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Sharif innovation station, North Habibollah, Hosseini Squ., Teymoury St., Tarasht
City
Tehran
Province
Tehran
Postal code
1459926609
Phone
+98 21 6600 4027
Email
info@tavaninstitute.ir

Person responsible for updating data

Contact

Name of organization / entity
Tavan Institute

Full name of responsible person
Ali Aghaei
Position
Master
Latest degree
Master
Other areas of specialty/work
Pharmacy
Street address
Sharif innovation station, North Habibollah, Hosseini Squ., Teymoury St., Tarasht
City
Tehran
Province
Tehran
Postal code
1459926609
Phone
+98 21 6600 4027
Email
info@tavaninstitute.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available